Intravenous acyclovir for the treatment of primary genital herpes

L. Corey, K. H. Fife, J. K. Benedetti, C. A. Winter, A. Fahnlander, J. D. Connor, M. A. Hintz, K. K. Holmes

Research output: Contribution to journalArticle

119 Scopus citations

Abstract

Thirty-one patients with first episodes of genital herpes were randomized in a double-blind fashion to intravenous treatment with saline placebo or acyclovir, 5 mg/kg body weight at 8-hour intervals, for 5 days. The median duration of viral shedding from genital lesions after the onset of therapy was significantly shorter for patients given acyclovir (2 days) than for those given placebo (13 days), p < 0.001. Viral shedding from the pharynx, cervix, urethra, and urine were also shorter in acyclovir-treated patients. (p ≤ 0.01 for each comparison). Local and systemic symptoms were shortened by a mean of 5 days and healing of genital lesions by a mean of 12 days in acyclovir-treated patients. (p < 0.01). Complications during treatment, such as extragenital lesions or urinary retention requiring catheterization, developed in four patients given placebo and in none given acyclovir. (p < 0.05). Intravenous acyclovir substantially decreases the symptoms, duration of lesions, and complications of primary genital herpes.

Original languageEnglish (US)
Pages (from-to)914-920
Number of pages7
JournalUnknown Journal
Volume98
Issue number6
DOIs
StatePublished - Jan 1 1983
Externally publishedYes

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint Dive into the research topics of 'Intravenous acyclovir for the treatment of primary genital herpes'. Together they form a unique fingerprint.

  • Cite this

    Corey, L., Fife, K. H., Benedetti, J. K., Winter, C. A., Fahnlander, A., Connor, J. D., Hintz, M. A., & Holmes, K. K. (1983). Intravenous acyclovir for the treatment of primary genital herpes. Unknown Journal, 98(6), 914-920. https://doi.org/10.7326/0003-4819-98-6-914